BI 456906
- Business
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Copenhagen, Denmark & Ingelheim, Germany: New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.…
Read More »